OBJECTIVE: To characterize the expression of CCL19 and CCL21 in rheumatoid arthritis (RA) synovial tissue (ST) and to examine their regulation and pathogenetic role in macrophages and RA ST fibroblasts. METHODS: Expression of CCL19 and CCL21 in RA and normal ST was demonstrated by immunohistochemistry analysis. CCL19 and CCL21 levels in synovial fluid (SF) from patients with osteoarthritis (OA), juvenile idiopathic arthritis, psoriatic arthritis (PsA), and RA were quantified by enzyme-linked immunosorbent assay (ELISA). Regulation of CCL19 and CCL21 expression in in vitro-differentiated RA peripheral blood macrophages as well as RA ST fibroblasts was determined by real-time reverse transcription-polymerase chain reaction. Proangiogenic factor production in CCL19- and CCL21-activated in vitro-differentiated peripheral blood macrophages and RA ST fibroblasts was examined by ELISA. RESULTS: CCL19 and CCL21 were elevated in RA ST compared to tissue from normal controls. Levels of CCL19 and CCL21 were greatly increased in RA and PsA SF versus OA SF. In RA macrophages and fibroblasts, expression of CCL19 was increased by stimulation with lipopolysaccharide, tumor necrosis factor α (TNFα), and interleukin-1β (IL-1β). However, CCL21 expression was modulated only by IL-1β in RA fibroblasts, and by TNFα and RA SF in RA macrophages. CCL19 and CCL21 activation induced vascular endothelial growth factor and angiotensin I (Ang I) production in RA ST fibroblasts and secretion of IL-8 and Ang I from macrophages. CONCLUSION: The findings of the present study identify, for the first time, regulators of CCL19 and CCL21 in RA fibroblasts and in vitro-differentiated RA peripheral blood macrophages and demonstrate a novel role of CCL19/CCL21 in angiogenesis in RA.
OBJECTIVE: To characterize the expression of CCL19 and CCL21 in rheumatoid arthritis (RA) synovial tissue (ST) and to examine their regulation and pathogenetic role in macrophages and RA ST fibroblasts. METHODS: Expression of CCL19 and CCL21 in RA and normal ST was demonstrated by immunohistochemistry analysis. CCL19 and CCL21 levels in synovial fluid (SF) from patients with osteoarthritis (OA), juvenile idiopathic arthritis, psoriatic arthritis (PsA), and RA were quantified by enzyme-linked immunosorbent assay (ELISA). Regulation of CCL19 and CCL21 expression in in vitro-differentiated RA peripheral blood macrophages as well as RA ST fibroblasts was determined by real-time reverse transcription-polymerase chain reaction. Proangiogenic factor production in CCL19- and CCL21-activated in vitro-differentiated peripheral blood macrophages and RA ST fibroblasts was examined by ELISA. RESULTS:CCL19 and CCL21 were elevated in RA ST compared to tissue from normal controls. Levels of CCL19 and CCL21 were greatly increased in RA and PsA SF versus OA SF. In RA macrophages and fibroblasts, expression of CCL19 was increased by stimulation with lipopolysaccharide, tumor necrosis factor α (TNFα), and interleukin-1β (IL-1β). However, CCL21 expression was modulated only by IL-1β in RA fibroblasts, and by TNFα and RA SF in RA macrophages. CCL19 and CCL21 activation induced vascular endothelial growth factor and angiotensin I (Ang I) production in RA ST fibroblasts and secretion of IL-8 and Ang I from macrophages. CONCLUSION: The findings of the present study identify, for the first time, regulators of CCL19 and CCL21 in RA fibroblasts and in vitro-differentiated RA peripheral blood macrophages and demonstrate a novel role of CCL19/CCL21 in angiogenesis in RA.
Authors: Sarah R Pickens; Michael V Volin; Arthur M Mandelin; Jay K Kolls; Richard M Pope; Shiva Shahrara Journal: J Immunol Date: 2010-02-19 Impact factor: 5.422
Authors: Shiva Shahrara; Sarah R Pickens; Arthur M Mandelin; William J Karpus; Qiquan Huang; Jay K Kolls; Richard M Pope Journal: J Immunol Date: 2010-03-12 Impact factor: 5.422
Authors: Nathan D Chamberlain; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; William Swedler; Arthur M Mandelin; Shiva Shahrara Journal: J Immunol Date: 2012-06-01 Impact factor: 5.422
Authors: John N Aucott; Mark J Soloski; Alison W Rebman; Lauren A Crowder; Lauren J Lahey; Catriona A Wagner; William H Robinson; Kathleen T Bechtold Journal: Clin Vaccine Immunol Date: 2016-09-06
Authors: Nathan D Chamberlain; Seung-jae Kim; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; Shiva Arami; Arthur M Mandelin; Shiva Shahrara Journal: Ann Rheum Dis Date: 2012-06-23 Impact factor: 19.103
Authors: Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Nicholas E Talarico; Arthur M Mandelin; Shiva Shahrara Journal: Arthritis Rheum Date: 2012-08
Authors: Sarah R Pickens; Nathan D Chamberlain; Michael V Volin; Richard M Pope; Nicholas E Talarico; Arthur M Mandelin; Shiva Shahrara Journal: Arthritis Rheum Date: 2011-10
Authors: John S Lewis; Bridgette D Furman; Evan Zeitler; Janet L Huebner; Virginia B Kraus; Farshid Guilak; Steven A Olson Journal: Arthritis Rheum Date: 2013-03
Authors: Allison L Mathes; Romy B Christmann; Giuseppina Stifano; Alsya J Affandi; Timothy R D J Radstake; G Alessandra Farina; Cristina Padilla; Sarah McLaughlin; Robert Lafyatis Journal: Ann Rheum Dis Date: 2013-07-19 Impact factor: 19.103